275 related articles for article (PubMed ID: 22056402)
1. Angiogenesis inhibition by the maleimide-based small molecule GNX-686.
Nowak-Sliwinska P; Storto M; Cataudella T; Ballini JP; Gatz R; Giorgio M; van den Bergh H; Plyte S; Wagnières G
Microvasc Res; 2012 Mar; 83(2):105-10. PubMed ID: 22056402
[TBL] [Abstract][Full Text] [Related]
2. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
3. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity.
Penn JS; Rajaratnam VS; Collier RJ; Clark AF
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):283-90. PubMed ID: 11133880
[TBL] [Abstract][Full Text] [Related]
4. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model.
Akkoyun I; Karabay G; Haberal N; Dagdeviren A; Yilmaz G; Oto S; Erkanli L; Akova YA
Acta Ophthalmol; 2012 Sep; 90(6):564-70. PubMed ID: 20698831
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenesis effects of endostatin in retinal neovascularization.
Bai YJ; Huang LZ; Zhou AY; Zhao M; Yu WZ; Li XX
J Ocul Pharmacol Ther; 2013 Sep; 29(7):619-26. PubMed ID: 23545016
[TBL] [Abstract][Full Text] [Related]
8. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
[TBL] [Abstract][Full Text] [Related]
9. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
10. Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity.
McCollum GW; Rajaratnam VS; Bullard LE; Yang R; Penn JS
Exp Eye Res; 2004 May; 78(5):987-95. PubMed ID: 15051479
[TBL] [Abstract][Full Text] [Related]
11. Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models.
Jhanji V; Liu H; Law K; Lee VY; Huang SF; Pang CP; Yam GH
Br J Ophthalmol; 2011 Sep; 95(9):1309-15. PubMed ID: 21719569
[TBL] [Abstract][Full Text] [Related]
12. Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide.
Jacoby DB; Dyskin E; Yalcin M; Kesavan K; Dahlberg W; Ratliff J; Johnson EW; Mousa SA
Anticancer Res; 2010 Jan; 30(1):39-46. PubMed ID: 20150615
[TBL] [Abstract][Full Text] [Related]
13. Rosmarinic acid suppresses retinal neovascularization via cell cycle arrest with increase of p21(WAF1) expression.
Kim JH; Lee BJ; Kim JH; Yu YS; Kim MY; Kim KW
Eur J Pharmacol; 2009 Aug; 615(1-3):150-4. PubMed ID: 19470386
[TBL] [Abstract][Full Text] [Related]
14. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
[TBL] [Abstract][Full Text] [Related]
15. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy.
Neu J; Afzal A; Pan H; Gallego E; Li N; Li Calzi S; Caballero S; Spoerri PE; Shaw LC; Grant MB
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3151-5. PubMed ID: 16799062
[TBL] [Abstract][Full Text] [Related]
16. CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo.
Dan H; Lei X; Huang X; Ma N; Xing Y; Shen Y
Microvasc Res; 2021 Jul; 136():104146. PubMed ID: 33610563
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
18. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.
Komi Y; Ohno O; Suzuki Y; Shimamura M; Shimokado K; Umezawa K; Kojima S
Jpn J Clin Oncol; 2007 Nov; 37(11):867-73. PubMed ID: 17956898
[TBL] [Abstract][Full Text] [Related]
20. Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo.
Pilorget A; Conesa M; Sarray S; Michaud-Levesque J; Daoud S; Kim KS; Demeule M; Marvaldi J; El Ayeb M; Marrakchi N; Béliveau R; Luis J
J Cell Physiol; 2007 May; 211(2):307-15. PubMed ID: 17323383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
